Role of CHIP as predisposing factor in t-MNs
| Primary disease (PD) . | n . | Age at t-MNs (y, median, range) . | CHIP at PD diagnosis (%) . | Frequently mutated genes* . | Reference . |
|---|---|---|---|---|---|
| NHL/HL MM Solid tumors | 3/1 2 1 | 56 (42-68) | 4 of 7 (57) | TP53 | 47 |
| NHL/HL APL/AML ALL | 7/2 4 1 | 62 (30-81) | 3 of 8 (21) | ASXL1 | 48 |
| NHL MM Solid tumors | 5 1 7 | 74 (70-82) | 8/13 (62) vs 15/56 (27) controls | TP53, TET2 | 49 |
| NHL/HL Solid tumors | 2/1 11 | 65 (28-77) | 10/14 (71) vs 17/54 (31) controls | TP53, TET2, DNMT3A, RUNX1, SRSF2 | 50 |
| NHL/HL MM/amyloidosis | 11/2 5 | 61 (41-71) | 7/10 (70) in PBSC grafts | TP53, DNMT3A | 51 |
| Hematological neoplasms Solid tumors | 35 | NA | 19 (54) | TP53 | 26 |
| Primary disease (PD) . | n . | Age at t-MNs (y, median, range) . | CHIP at PD diagnosis (%) . | Frequently mutated genes* . | Reference . |
|---|---|---|---|---|---|
| NHL/HL MM Solid tumors | 3/1 2 1 | 56 (42-68) | 4 of 7 (57) | TP53 | 47 |
| NHL/HL APL/AML ALL | 7/2 4 1 | 62 (30-81) | 3 of 8 (21) | ASXL1 | 48 |
| NHL MM Solid tumors | 5 1 7 | 74 (70-82) | 8/13 (62) vs 15/56 (27) controls | TP53, TET2 | 49 |
| NHL/HL Solid tumors | 2/1 11 | 65 (28-77) | 10/14 (71) vs 17/54 (31) controls | TP53, TET2, DNMT3A, RUNX1, SRSF2 | 50 |
| NHL/HL MM/amyloidosis | 11/2 5 | 61 (41-71) | 7/10 (70) in PBSC grafts | TP53, DNMT3A | 51 |
| Hematological neoplasms Solid tumors | 35 | NA | 19 (54) | TP53 | 26 |
HSCT, allogeneic stem cell transplantation; MM, multiple myeloma; NA, not applicable; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood stem cell.
More than 1 patient.